GSK China: what about the others?
This article was originally published in Scrip
Executive Summary
The corruption affair surrounding GlaxoSmithKline in China has raised many more questions than have so far been answered. With Chinese officials intimating that GlaxoSmithKline will not be the only company to come under the spotlight, one major question is, how many other firms will be drawn in?